Risk of antibiotics associated with Clostridioides difficile infection: Antibiotic stewardship in action
| dc.contributor.author | Dysangco, Andrew T. | |
| dc.contributor.author | Pierce, Tamra M. | |
| dc.contributor.author | Bravata, Dawn M. | |
| dc.contributor.department | Medicine, School of Medicine | |
| dc.date.accessioned | 2023-10-03T13:46:42Z | |
| dc.date.available | 2023-10-03T13:46:42Z | |
| dc.date.issued | 2022-08-26 | |
| dc.description.abstract | We examined risk associated with antibiotics used for Clostridioides difficile infection (CDI) at a single site from 2018 through 2020. Overall, 78 patients had nonrecurrent infections. Among inpatient antibiotics, intravenous meropenem had the highest CDI rate (3.56 per 1,000 days of therapy; n = 2 cases). Among outpatient antibiotics, metronidazole had the highest rate (0.071 per 1,000 pills dispensed; n = 3 cases). | |
| dc.eprint.version | Final published version | |
| dc.identifier.citation | Dysangco AT, Pierce TM, Bravata DM. Risk of antibiotics associated with Clostridioides difficile infection: Antibiotic stewardship in action. Antimicrob Steward Healthc Epidemiol. 2022;2(1):e146. Published 2022 Aug 26. doi:10.1017/ash.2022.286 | |
| dc.identifier.uri | https://hdl.handle.net/1805/35958 | |
| dc.language.iso | en_US | |
| dc.publisher | Cambridge University Press | |
| dc.relation.isversionof | 10.1017/ash.2022.286 | |
| dc.relation.journal | Antimicrobial Stewardship & Healthcare Epidemiology | |
| dc.rights | Attribution 4.0 International | en |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.source | PMC | |
| dc.subject | Clostridioides difficile infection (CDI) | |
| dc.subject | Intravenous meropenem | |
| dc.subject | Metronidazole | |
| dc.title | Risk of antibiotics associated with Clostridioides difficile infection: Antibiotic stewardship in action | |
| dc.type | Article |